Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical Company Limited, established in 1943 and listed on the Shenzhen Stock Exchange in 1997, is a prominent pharmaceutical manufacturing company in China. Formerly known as Shandong Xinhua Pharmaceutical Factory, the company is recognized as a key player in the production and export of analgesics in Asia and is a significant manufacturer of drugs for the cardio cerebrovascular system, anti-infection, and central nervous system. The company has a strong influence in the chemical and pharmaceutical industry within the People's Republic of China. The company's operations encompass a comprehensive industry chain that includes medical intermediates, bulk pharmaceuticals, and preparations. Shandong Xinhua Pharmaceutical is the largest production and export base for antipyretic analgesic drugs in the country, with several of its products, such as ibuprofen and aspirin, leading the market in terms of share. The company has achieved various international certifications, including FDA approval for 27 products and European EDQM certification for 16 products, and exports to over 50 countries. With a focus on technological innovation and collaboration with research institutions, the company is recognized as a national high and new technology enterprise.

The Company enjoys an advantage of large scale operation, and is the largest production and export base for antipyretic analgesic drugs. The Company has formed a relatively complete industry chain with strong industrial supporting capability. The Company has an advantage in fundamental management and successively passed the ISO9001, ISO14001, ISO10012 and ISO22000 certifications. The Company has an advantage of international operation. With 27 items of the Company's products having passed the American FDA certification and 16 items having obtained the European COS certificate, the Company’s products were sold to more than 50 countries and regions in the world. The Company is one of the first 15 pioneering enterprises in the PRC which implement a global strategy and one of the national top ten exporters of preparations. The Company has an advantage in technological innovation. The Company is a national high and new technology enterprise, a key high and new technology enterprise under the National Torch Program, and a key enterprise in the bio-pharmaceutical industrial base under the National Torch Program. The Company has a national-level enterprise technology centre, an established enterprise post-doctoral research station, and has extensive cooperation with more than 50 scientific and research institutions and universities.